

9. National Center for Biotechnology Information. ClinVar; [VCV000120303.32] [Internet]. [cited 2022 May 24]. Available from: <https://www.ncbi.nlm.nih.gov/clinvar/variation/120303/>
10. National Center for Biotechnology Information. ClinVar; [VCV000956376.3] [Internet]. [cited 2022 May 23]. Available from: <https://www.ncbi.nlm.nih.gov/clinvar/variation/956376/>
11. Richards S, Aziz N, Bale S, et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015;17(5):405-24.
12. Infevers. ADA2 sequence variants [Internet]. [cited 2023 May 7]. Available from: <https://infevers.umai-montpellier.fr/web/search.php?n=20>
13. Jee H, Huang Z, Baxter S, et al. Comprehensive analysis of ADA2 genetic variants and estimation of carrier frequency driven by a function-based approach. *J Allergy Clin Immunol*. 2022;149(1):379-87.
14. Maccora I, Maniscalco V, Campani S, et al. A wide spectrum of phenotype of deficiency of deaminase 2 (DADA2): a systematic literature review. *Orphanet J Rare Dis*. 2023;18:117.
15. Rakesh Kumar P, Aaqib Zaffar B, Saniya S, et al. Deficiency of Human Adenosine Deaminase Type 2 - A Diagnostic Conundrum for the Hematologist. *Front Immunol*. 2022;13:869570.
16. Belot A, Wassmer E, Twilt M, et al. Mutations in CECR1 associated with a neutrophil signature in peripheral blood. *Pediatr Rheumatol Online J*. 2014;12:44.
17. Caorsi R, Penco F, Grossi A, et al. ADA2 deficiency (DADA2) as an unrecognized cause of early onset polyarteritis nodosa and stroke: a multicentre national study. *Ann Rheum Dis*. 2017;76(10):1648-56.
18. Lee PY, Davidson BA, Abraham RS, et al. Evaluation and Management of Deficiency of Adenosine Deaminase 2: An International Consensus Statement. *JAMA Netw Open*. 2023;6(5):e2315894.
19. Ombrello AK, Qin J, Hoffmann PM, et al. Treatment Strategies for Deficiency of Adenosine Deaminase 2. *N Engl J Med*. 2019;380(16):1582-4.
20. Thorarinsdottir K, Camponeschi A, Cavallini N, et al. CD21-/low B cells in human blood are memory cells. *Clin Exp Immunol*. 2016;185(2):252-62.
21. Yap JY, Moens L, Lin MW, et al. Intrinsic Defects in B Cell Development and Differentiation, T Cell Exhaustion and Altered Unconventional T Cell Generation Characterize Human Adenosine Deaminase Type 2 Deficiency. *J Clin Immunol*. 2021;41(8):1915-35.
22. Schnappauf O, Zhou Q, Moura NS, et al. Deficiency of Adenosine Deaminase 2 (DADA2): Hidden Variants, Reduced Penetrance, and Unusual Inheritance. *J Clin Immunol*. 2020;40(6):917-26.
23. Hashem H, Bucciol G, Ozen S, et al. Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients. *J Clin Immunol*. 2021;41(7):1633-47.
24. Hashem H, Dimitrova D, Meyts I. Allogeneic Hematopoietic Cell Transplantation for Patients With Deficiency of Adenosine Deaminase 2 (DADA2): Approaches, Obstacles and Special Considerations. *Front Immunol*. 2022;13:932385.
25. Elbracht M, Mull M, Wagner N, et al. Stroke as Initial Manifestation of Adenosine Deaminase 2 Deficiency. *Neuropediatrics*. 2017;48(2):111-4.

ON-LINE KURZ

On-line kurz Kardiologie

PŘEDNÁŠKY

- **Co je u nových tabulek SCORE opravdu důležité? Modelové situace v ordinaci a jak je řešit** – MUDr. Jaromír Ožana, MUDr. Michal Mačák
- **Speciality v léčbě hypertenze** – doc. MUDr. Ondřej Petrák, Ph.D.
- **Aktuality a praktické tipy v léčbě dyslipidemie** – MUDr. Eva Tůmová, Ph.D.
- **Co (ne)budeme potřebovat od biochemické laboratoře pro stanovení kardiovaskulárního rizika?** – prof. MUDr. Michal Vrablík, Ph.D.

ODBOBNÝ GARANT:

prof. MUDr. Michal Vrablík, Ph.D.
III. interní klinika 1. LF UK a VFN v Praze

POŘADATEL: SOLEN, s. r. o.

POČET
KREDITŮ **2**

Registrace
ZDARMA

TERMÍN
září 2023
až srpen 2024
dostupný na
online.solen.cz

PARTNER

SERVIER
moved by you

